= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Santoru

MSACL 2018 EU Abstract

Topic: Metabolomics

Podium Presentation in the Ether on Wednesday at 9:40 (Chair: Julijana Ivanisevic)

Understanding the Interplay Between Inflammatory Lipid Signaling and Demyelination Process: A Lipidomics Approach Applied to 3D Human Brain Model

Maria Laura Santoru (Presenter)
University of Cagliari / University of Lausanne

Authors: Maria Laura Santoru (1,3), H├ęctor Gallart-Ayala (1), David Pamies (2,4), Tony Teav (1), Luigi Atzori (3), Marie Gabrielle Zurich (2,4) and Julijana Ivanisevic (1)
(1) Metabolomics Platform, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland (2) Department of Physiology, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland (3) Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy (4)Swiss Center for Applied Human Toxicology (SCAHT), Switzerland

Abstract

Demyelination and inflammation are two main features of multiple sclerosis. It has been proved that lipids play an important role in these two processes and to elucidate their mechanism of action in MS, a lipidomics approach was applied to iPSC-derived human 3D brain spheres system challenged by a treatment with cytokines to induce the demyelination. Combining targeted and untargeted lipidomics, we detected different classes of lipids in both spheres and their corresponding media. Among the measured lipid species, PAF and PAF related species were found to be significantly upregulated in the cytokine-treated spheres while the PUFA species and derived eicosanoids were increased in the spent media, suggesting a link between the early stage of inflammation process in MS and activated lipid signaling.


Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no